(EMAILWIRE.COM, July 07, 2009 ) DALLAS, Texas - BeaconEquity.com announces the publication of an article covering Alcon’s successful completion of phase I study of NovaBay's patented lead Aganocide and the beginning of phase II.

Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m

In the article the author writes:

“Swiss-based Alcon Inc. (NYSE: ACL) and partner NovaBay Pharmaceuticals (NYSE-AMEX: NBY) of Emeryville, Calif., jointly announced Alcon has begun the phase II clinical trial of NovaBay's patented lead Aganocide compound, NVC-422, to treat viral conjunctivitis, commonly referred to as “pink eye” or “Madras eye.” Conjunctivitis is a common ocular disease, described by an inflammation of the conjunctiva (inner surface of the eyelids). The disease is contagiously transmitted from person to person.”

Alcon will soon launch its phase II clinical trial to show safety and efficacy of NVC-422:

“Phase II will be a multi-center, randomized, placebo-controlled trial to show safety and efficacy of NVC-422 with patients with viral conjunctivitis. The study will involve 250 patients at more than 30 medical centers.”

To read the entire article visit http://www.beaconequity.com/m

Join the fastest growing investor community at: http://www.stockhideout.com/

BeaconEquity.com’s Market News is one of the fastest growing small-cap blogs in the investment community. Beacon is the authority on research in the small-cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.

We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

BeaconEquity.com is one of the industry’s largest small-cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.


Source: BeaconEquity.com

Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com

Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.